

REVIEW ARTICLE

CURRENT CONCEPTS

Tuberculosis

Alimuddin Zumla, M.D., Ph.D., Mario Raviglione, M.D., Richard Hafner, M.D.,
and C. Fordham von Reyn, M.D.

DESPITE THE AVAILABILITY OF A CHEAP AND EFFECTIVE TREATMENT, tuberculosis still accounts for millions of cases of active disease and deaths worldwide. The disease disproportionately affects the poorest persons in both high-income and developing countries.¹ However, recent advances in diagnostics, drugs, and vaccines and enhanced implementation of existing interventions have increased the prospects for improved clinical care and global tuberculosis control.

EPIDEMIOLOGY

In 2011, there were 8.7 million new cases of active tuberculosis worldwide (13% of which involved coinfection with the human immunodeficiency virus [HIV]) and 1.4 million deaths, including 430,000 deaths among HIV-infected patients¹ representing a slight decrease from peak numbers in the mid-2000s (Fig. 1). It has been estimated that there were 310,000 incident cases of multidrug-resistant tuberculosis, caused by organisms resistant to at least isoniazid and rifampin, among patients who were reported to have tuberculosis in 2011 (Fig. 2). More than 60% of these patients were in China, India, the Russian Federation, Pakistan, and South Africa.^{1,2} A total of 84 countries have reported cases of extensively drug-resistant tuberculosis, a subset of multidrug-resistant tuberculosis with added resistance to all fluoroquinolones plus any of the three injectable antituberculosis drugs, kanamycin, amikacin, and capreomycin.¹⁻³ Sub-Saharan Africa has the highest rates of active tuberculosis per capita, driven primarily by the HIV epidemic.¹ The absolute number of cases is highest in Asia, with India and China having the greatest burden of disease globally.¹ In the United States and most Western European countries, the majority of cases occur in foreign-born residents and recent immigrants from countries in which tuberculosis is endemic.⁴⁻⁶

PATHOGENESIS


Patients with active pulmonary tuberculosis are the source of *Mycobacterium tuberculosis*. In more than 90% of persons infected with *M. tuberculosis*, the pathogen is contained as asymptomatic latent infection. Recent studies raise the possibility that some persons acquire and eliminate acute infection with *M. tuberculosis*.⁷ The risk of active disease is estimated to be approximately 5% in the 18 months after initial infection and then approximately 5% for the remaining lifetime.⁸ An estimated 2 billion persons worldwide have latent infection and are at risk for reactivation.¹ Contained latent infection reduces the risk of reinfection on repeated exposure, whereas active tuberculosis is associated with an increased risk of a second episode of tuberculosis on reexposure (Fig. S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).⁸⁻¹⁰

From the Department of Infection, Division of Infection and Immunity, University College London Medical School, London (A.Z.); STOP TB Department, World Health Organization, Geneva (M.R.); the Tuberculosis Clinical Research Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (R.H.); and the Section of Infectious Disease and International Health, Geisel School of Medicine at Dartmouth, Hanover, NH (C.F.R.). Address reprint requests to Dr. Zumla at the Division of Infection and Immunity, Centre for Clinical Microbiology, 2nd Fl., UCL Royal Free Campus, Rowland Hill St., London NW3 0PE, United Kingdom, or at a.zumla@ucl.ac.uk.

N Engl J Med 2013;368:745-55.

DOI: 10.1056/NEJMra1200894

Copyright © 2013 Massachusetts Medical Society.



Drug-resistant strains of *M. tuberculosis* arise from spontaneous chromosomal mutations at a predictable low frequency. Selection pressure that is caused by misuse of antituberculosis drugs, such as monotherapy or the addition of single drugs to failing regimens, results in the emergence of resistant mutants (acquired resistance). Transmission of such resistant strains to another

person may result in infection and eventually disease (primary resistance). Outbreaks of highly fatal drug-resistant infection have been documented in several settings, especially those in which the prevalence of HIV infection is high.¹¹⁻¹³ Recent reports describing totally drug-resistant tuberculosis require confirmation.^{14,15} The failure to detect drug resistance results in the pre-




Figure 2. Global Numbers of Cases of Multidrug-Resistant Tuberculosis.

Shown are the estimated numbers of cases of multidrug-resistant disease (including extensively drug-resistant disease) among cases of pulmonary tuberculosis that were officially reported in 2011.

scription of inappropriate regimens, treatment failure, increased mortality, and further transmission of drug-resistant tuberculosis.¹⁶

CLINICAL FEATURES

The classic clinical features of pulmonary tuberculosis include chronic cough, sputum production, appetite loss, weight loss, fever, night sweats, and hemoptysis.¹⁷ Extrapulmonary tuberculosis occurs in 10 to 42% of patients, depending on race or ethnic background, age, presence or absence of underlying disease, genotype of the *M. tuberculosis* strain, and immune status.¹⁸ Extrapulmonary tuberculosis can affect any organ in the body, has varied and protean clinical manifestations, and therefore requires a high index of clinical suspicion.

HIV coinfection poses special challenges to clinical management in patients with active tuberculosis. The risk of active tuberculosis increases soon after infection with HIV,¹⁹ and the manifestations of pulmonary tuberculosis at this stage are similar to those in HIV-negative persons. At CD4 counts of less than 200 per cubic

millimeter, the presentation of tuberculosis may be atypical, with subtle infiltrates, pleural effusions, hilar lymphadenopathy, and other forms of extrapulmonary tuberculosis in as many as 50% of patients. At CD4 counts of less than 75 per cubic millimeter, pulmonary findings may be absent, and disseminated tuberculosis, manifested as a nonspecific, chronic febrile illness with widespread organ involvement and mycobacteremia, is more frequent, with high early mortality; polyclonal disease has also been described.²⁰ Such cases may be mistakenly diagnosed as other infectious diseases and are often identified only on autopsy.²¹

Asymptomatic, subclinical tuberculosis, with negative findings on a sputum smear and chest radiography and positive culture results, is a common feature of HIV-associated tuberculosis and may account for 10% of cases in regions in which tuberculosis is endemic.^{17,22,23} Up to 25% of patients presenting for HIV care in such regions have undiagnosed active tuberculosis.¹ Therefore, screening for tuberculosis is recommended for all patients with HIV infection to identify patients with active disease and before

instituting isoniazid preventive therapy in the remainder. The presence of any one of four symptoms (cough, fever, night sweats, or weight loss) has been shown to have sensitivity in the range of 80% for identifying patients in whom further diagnostic evaluation is warranted, even in resource-constrained regions.²⁴ Proactive screening for tuberculosis is recommended in areas where the disease is highly endemic, since subclinical tuberculosis in patients with HIV infection or noncommunicable diseases (e.g., diabetes mellitus and tobacco-related chronic lung disease) may otherwise be missed.^{24,25}

DIAGNOSIS

LATENT INFECTION

Screening and treatment for latent *M. tuberculosis* infection are indicated for groups in which the prevalence of latent infection is high (e.g., foreign-born persons from regions in which tuberculosis is endemic), those in whom the risk of reactivated disease is high (e.g., patients with HIV infection or diabetes and patients receiving immunosuppressive therapy), and those with both factors (e.g., recent contacts of patients with tuberculosis).^{26,27} Latent infection can be diagnosed with either a tuberculin skin test (Fig. S2 in the Supplementary Appendix) or an interferon-gamma release assay. Specific guidelines from the Centers for Disease Control and Prevention in the United States,²⁸ the National Institute for Health and Clinical Excellence in the United Kingdom,²⁹ and the European Centre for Disease Prevention and Control³⁰ recommend the use of the interferon-gamma release assay and tuberculin skin test for screening for latent *M. tuberculosis* infection in various age and risk groups. The tuberculin skin test is less expensive and is therefore preferred in low-income regions. It is as sensitive as the interferon-gamma release assay but less specific.³¹

ACTIVE TUBERCULOSIS

Sputum microscopy and culture in liquid medium with subsequent drug-susceptibility testing are currently recommended as standard methods for diagnosing active tuberculosis. The use of solid culture medium is more cost-effective in resource-poor countries. Interferon-gamma release assays and tuberculin skin tests have no role in the diagnosis of active disease.²⁸⁻³³ Nucleic acid amplification tests, imaging, and histopathological examination of biopsy samples supplement these

evaluations. In resource-constrained settings with a high prevalence of tuberculosis and HIV infection, an estimated 30% of all patients with tuberculosis and more than 90% of those with multidrug-resistant and extensively drug-resistant tuberculosis do not receive a diagnosis.¹⁻³

A new molecular diagnostic test called Xpert MTB/RIF assay detects *M. tuberculosis* complex within 2 hours, with an assay sensitivity that is much higher than that of smear microscopy.³⁴ In HIV-infected patients, the test has a rate of case detection that is increased by 45%, as compared with smear microscopy.³⁵ This molecular assay has the potential to improve the performance of national tuberculosis programs and is currently being implemented in district-level laboratories in 67 countries with a high prevalence of tuberculosis.¹ It is available in Europe and is being examined for approval in the United States.

DRUG-RESISTANT TUBERCULOSIS

The current standard for first-line drug-susceptibility testing is an automated liquid culture system, which requires 4 to 13 days for results. Commercial molecular line-probe assays can yield results in 24 hours, once they have been validated against automated liquid culture.³⁶⁻³⁸ Within 2 hours, the Xpert MTB/RIF assay concurrently gives results on rifampin resistance, a proxy of multidrug-resistant tuberculosis in settings in which there is a high prevalence of drug resistance, since rifampin resistance in the absence of isoniazid resistance is uncommon. Assay modifications have been introduced to reduce false positive results with respect to rifampin resistance.³⁹ The World Health Organization (WHO) recommends that standard drug-susceptibility testing be performed at the same time that the Xpert MTB/RIF assay is performed to confirm rifampin resistance and the susceptibility of the *M. tuberculosis* isolate to other drugs.⁴⁰ Other screening tests for drug resistance include the microscopic-observation drug-susceptibility (MODS) assay, the nitrate reductase assay, and colorimetric reductase methods. The MODS assay simultaneously detects *M. tuberculosis* bacilli, on the basis of cording formation, and isoniazid and rifampin resistance.⁴¹ Since most of these methods are not currently available in countries in which tuberculosis is highly endemic, it is estimated that only 10% of cases of multidrug-resistant tuberculosis are currently diagnosed worldwide and only half of them receive appropriate treatment.¹⁻³

Table 1. Current Recommendations for Tuberculosis Treatment.

Type of Infection	Recommended Regimen	Comments
Active disease		
Newly diagnosed cases that are not multidrug-resistant	Isoniazid, rifampin, ethambutol, and pyrazinamide for 2 mo (intensive phase), followed by isoniazid and rifampin for 4 mo (continuation phase)	Pyridoxine supplementation recommended to prevent isoniazid-induced neuropathy
Multidrug-resistant disease	Four second-line antituberculosis drugs (as well as pyrazinamide), including a fluoroquinolone, a parenteral agent, ethionamide or prothionamide, and either cycloserine or para-aminosalicylic acid if cycloserine cannot be used	Initial treatment based on local disease patterns and pending drug-susceptibility results; later-generation fluoroquinolones (e.g., moxifloxacin or levofloxacin) preferred
Latent infection		
	Isoniazid at a dose of 300 mg daily for at least 6 mo and preferably for 9 mo	Recommended for 9 mo or more in HIV-infected persons; daily administration for 6 mo also an option but with lower efficacy; extension to 36 mo further reduces risk among HIV-positive patients in regions in which tuberculosis is endemic
	Isoniazid at a dose of 900 mg plus rifapentine at a dose of 900 mg weekly for 3 mo (directly observed therapy)	Studied with directly observed therapy in predominantly HIV-uninfected persons; higher completion rates and equal efficacy, as compared with isoniazid for 9 mo
	Rifampin at a dose of 600 mg daily for 4 mo	Shown to be effective in persons with silicosis
	Isoniazid at a dose of 300 mg plus rifampin at a dose of 600 mg daily for 3 mo	Effective alternative for HIV-infected persons
	Isoniazid at a dose of 900 mg plus rifampin at a dose of 600 mg twice weekly for 3 mo	Another effective alternative for HIV-infected persons

TREATMENT

LATENT INFECTION

Persons with latent *M. tuberculosis* infection who are at increased risk for active tuberculosis require preventive treatment.^{28,42} The preferred regimen is isoniazid alone for 9 months or for a longer duration in HIV-infected persons in areas with a high prevalence of tuberculosis.^{43,44} Recently, directly observed weekly administration of isoniazid and rifapentine for 12 weeks has been shown to be as effective as isoniazid alone in adults without HIV infection in countries with a low burden of tuberculosis. This regimen was associated with fewer serious adverse events than 9 months of isoniazid alone, although treatment discontinuation because of an adverse event was more common (Table 1).⁴⁵ The trial is continuing to assess safety and effectiveness in children and HIV-infected persons.

Current WHO guidelines⁴⁴ recommend that all HIV-infected persons with positive or unknown results on the tuberculin skin test and without active tuberculosis who are living in resource-

constrained, high-burden countries receive preventive therapy with isoniazid for at least 6 months. Three regimens are effective for the prevention of active tuberculosis in HIV-infected persons: daily isoniazid for 6 to 9 months, daily rifampin and isoniazid for 3 months, and rifampin and isoniazid twice weekly for 3 months.^{43,44} Rifampin-containing regimens have higher rates of drug toxicity than those that do not include rifampin.⁴⁴⁻⁴⁶ The difficulty of diagnosing active tuberculosis in patients with HIV coinfection accounts in part for the slow adoption of isoniazid preventive therapy in clinical practice. Only patients with a positive tuberculin skin test who are receiving preventive therapy with isoniazid have decreased rates of active tuberculosis and death,⁴⁶ and protection against tuberculosis wanes within a few months after cessation of isoniazid therapy. A trial in Botswana recently showed that 36 months of preventive therapy with isoniazid, as compared with 6 months of therapy, reduced the subsequent rate of tuberculosis by 43%.⁴⁷ However, compliance with such a long-term regimen may be poor.⁴⁴ A daily regimen of rifapentine

Table 2. Status of Selected Trials of Tuberculosis Treatments.*

Trial or Investigational Drug		Description	Comments
Treatment of drug-sensitive active disease			
REMOx		Standard 6-mo regimen vs. two 4-mo regimens including moxifloxacin	Results in 2014 have potential to shorten standard therapy to 4 mo
OFLOTUB III		Standard 6-mo regimen vs. 4-mo regimen including gatifloxacin	Results by mid-2013 have potential to shorten standard therapy to 4 mo
RIFAQUIN		Two experimental groups in which moxifloxacin is substituted for ethambutol for 2 mo, followed by moxifloxacin plus rifapentine twice weekly for 2 mo or moxifloxacin plus rifapentine weekly for 4 mo	Results expected by mid-2013
Multiple trials		Increased doses of rifampin and rifapentine	Higher doses of rifamycins may permit shorter regimens with standard drugs
Treatment of drug-resistant active disease			
Bedaquiline (TMC207)		Background therapy for multidrug-resistant disease plus bedaquiline	Mycobacterial ATP synthase inhibitor shown to improve sputum conversion at 8 wk; also to be studied in new regimens for drug-sensitive tuberculosis
Delamanid (OPC-67683)		Background therapy for multidrug-resistant disease plus delamanid	A nitroimidazole with activity against replicating bacilli through inhibition of mycolic acid synthesis; active against nonreplicating bacilli through generation of reactive nitrogen intermediates; shown to improve sputum-culture conversion at 8 wk
PA-824		PA-824 combined with moxifloxacin and pyrazinamide is being studied in a phase 2b trial (8 wk) for treatment of drug-sensitive and drug-resistant disease	A nitroimidazole with the same mechanism of action as delamanid; when combined with moxifloxacin and pyrazinamide, has high bactericidal activity at 14 days, suggesting promise for treatment of sensitive and resistant disease
Linezolid		Background therapy plus linezolid added immediately or 2 mo later in patients with extensively drug-resistant disease	A marketed oxazolidinone that improved sputum-culture conversion at 4 mo in a group receiving immediate versus delayed linezolid; for both linezolid regimens, 89% of patients had sputum-culture conversion on solid medium by 6 mo; high rate of peripheral neuropathy, including some cases of optic neuropathy
Sutezolid		Dose-ranging phase 2a trial completed	Analogue of linezolid that may have improved activity
AZD 5847		Phase 2a trial under way	More highly modified oxazolidinone
SQ109		Phase 2a trial completed; phase 2b combination trials to begin early in 2013	An ethylenediamine-based compound that is structurally related to ethambutol but has an entirely different mechanism of action

Empirical treatment of active disease	
PROMPT	Designed to reduce mortality from undiagnosed tuberculosis in HIV-infected patients
REMEMBER	Designed to reduce mortality from undiagnosed tuberculosis in HIV-infected patients
Prevention of active disease in patients with latent infection	
ACTG 5279	Designed to determine whether shorter treatment is effective in HIV-positive patients

* A full listing of all trial references or clinical trial numbers is provided in the Supplementary Appendix at NEJM.org. ACTG 5279 denotes Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection, OFLOTUB Randomized, Open-Label, Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen versus Standard Regimen for the treatment of Adult Patients with Pulmonary Tuberculosis; PROMPT Prevention of Early Mortality by Presumptive Tuberculosis Treatment; REMEMBER Reducing Early Mortality and Morbidity by Empiric Tuberculosis Treatment, REMox Rapid Evaluation of Moxifloxacin in Tuberculosis, and RIFAQUIN International Multicenter Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis.

and isoniazid for 1 month is also being studied (Table 2). Studies have been suggested to investigate targeted use of preventive therapy with isoniazid on a continuous or recurring basis in persons with HIV infection who have a positive tuberculin skin test.⁴⁸

DRUG-SENSITIVE ACTIVE TUBERCULOSIS

Effective tuberculosis treatment requires accurate and early diagnosis, screening for drug resistance and HIV, the administration of effective regimens under supervision, and the provision of support to patients for compliance throughout the course of treatment. The current standard four-drug treatment regimen of first-line drugs (isoniazid, rifampin, pyrazinamide, and ethambutol) achieves cure rates of more than 95% in trial conditions and more than 90% in treatment under the oversight of tuberculosis-control programs.^{1,49} Treatment requires a minimum of 6 months in two phases: 2 months of all four drugs in the intensive phase and 4 months of isoniazid and rifampin in the continuation stage (Table 1). Risk factors for relapse include cavitation, extensive disease, immunosuppression, and a sputum culture that remains positive at 8 weeks. If any of these risk factors is present, therapy may be extended for up to 9 months. Challenges with current therapy include inconsistent drug quality, the need to ensure that drug administration is directly observed and that other support is provided to patients, treatment interruptions and changes in regimen because of side effects, toxic effects, pharmacokinetic interactions (particularly with antiretroviral therapy in patients with HIV coinfection),⁵⁰ and compliance issues owing to the lengthy treatment period. Several trials in progress are adding or substituting fluoroquinolones or testing higher doses of rifamycins in an attempt to shorten standard therapy to 4 months (Table 2).

TUBERCULOSIS AND HIV COINFECTION

Tuberculosis leads to an increase in HIV replication and accelerates progression of HIV infection, with attendant high mortality. Early initiation of antiretroviral therapy results in a reduction in mortality; among patients with tuberculosis who do not receive antiretroviral therapy, those with very low numbers of CD4+ cells have a high short-term risk of death.⁵⁰⁻⁵² WHO recommends that antiretroviral therapy be started within the

first 8 weeks after the initiation of tuberculosis treatment and that patients with a CD4+ cell count of less than 50 per cubic millimeter receive antiretroviral therapy within the first 2 weeks.⁴² One exception is patients with tuberculous meningitis, in whom the early initiation of antiretroviral therapy does not improve outcomes and results in an increased risk of adverse events.⁴²

The immune reconstitution inflammatory syndrome (IRIS) occurs in at least 10% of HIV-infected patients who start antiretroviral therapy during tuberculosis treatment. These cases of IRIS include both new cases of active tuberculosis detected after the initiation of antiretroviral therapy (called unmasking IRIS) and clinical worsening during tuberculosis treatment after the initiation of antiretroviral therapy (called paradoxical IRIS).⁵³ The most common manifestations of IRIS are new-onset or worsening respiratory symptoms and increased lymphadenopathy. IRIS is more common in patients who have a reduced number of CD4+ cells and those in whom antiretroviral therapy was initiated early in the course of tuberculosis treatment, with rates approaching 50% among patients with a CD4+ cell count of less than 50 per cubic millimeter who started to receive antiretroviral therapy within 4 weeks after the start of tuberculosis treatment.⁵³ For antiretroviral therapy in patients with active tuberculosis, regimens with non-nucleoside reverse transcriptase inhibitors are preferred, and efavirenz is the drug of first choice.⁵⁴

The use of rifampin significantly reduces serum concentrations of protease inhibitors.⁵⁵ Studies of the substitution of rifabutin for rifampin and increased doses of boosted protease inhibitors to avoid this reduction are under way.⁵⁵ Patients with HIV-associated tuberculosis should also receive prophylaxis with trimethoprim-sulfamethoxazole. In two clinical trials — the Prevention of Early Mortality by Presumptive Tuberculosis Treatment (PROMPT) study⁵⁶ and the Reducing Early Mortality and Morbidity by Empiric Tuberculosis Treatment (REMEMBER) study⁵⁷ — investigators are evaluating the use of early empirical tuberculosis therapy to reduce the high rate of death among patients living in tuberculosis-endemic countries who have a CD4+ cell count of less than 50 per cubic millimeter

but who do not have probable or confirmed tuberculosis (Table 2).

MULTIDRUG-RESISTANT TUBERCULOSIS

The treatment of multidrug-resistant tuberculosis is based on expert opinion and requires the creation of combination drug regimens chosen from five hierarchical groups of first-line and second-line drugs^{58,59} (Table S1 in the Supplementary Appendix). Such therapy is associated with a high risk of intolerance and serious toxic effects. Regimens may be chosen on a standardized or empirical basis and then switched to individualized therapy after data regarding drug-susceptibility testing become available. However, reliable drug-susceptibility testing is not widely available in regions in which tuberculosis is endemic, particularly for second-line drugs. WHO treatment guidelines for multidrug-resistant tuberculosis recommend that the intensive phase of therapy be administered for at least 8 months.^{58,59} A fluoroquinolone and an injectable agent should routinely be included to provide a regimen with at least four second-line drugs that will have certain or nearly certain effectiveness, as well as pyrazinamide.

Such therapy should be administered for at least 20 months in patients who have not received previous treatment for multidrug-resistant tuberculosis and for up to 30 months in those who have received previous treatment. An observational study showed that a shorter regimen, with treatment given for 9 to 12 months (the so-called Bangladesh regimen), had acceptable efficacy with fewer adverse reactions⁶⁰ in a population with no previous exposure to second-line drugs. This regimen is being more widely evaluated in the ongoing Standardized Treatment Regimen of Antituberculosis Drugs for Patients with Multidrug-Resistant Tuberculosis (STREAM) trial.⁶¹ Since most of the recommended drugs have serious side effects that render treatment particularly difficult, expert consultation is always advised for the treatment of multidrug-resistant tuberculosis (Table S2 in the Supplementary Appendix).

Extensively drug-resistant tuberculosis is extremely difficult to diagnose and treat in countries in which the disease is endemic. The condition has been associated with death rates as high

as 98% among HIV-infected persons.^{12,13,62,63} Several new drugs with activity against multidrug-resistant and extensively drug-resistant tuberculosis have shown promise in early trials and are being investigated further (Table S3 in the Supplementary Appendix).

NEW DRUGS

Five classes of new drugs are being investigated in trials. Of these drugs, two classes (nitroimidazoles and oxazolidinones) and two drugs (bedaquiline and SQ-109) have new mechanisms of action for tuberculosis (Table S3 in the Supplementary Appendix). Phase 2 trials of bedaquiline or delamanid added to background therapy for multidrug-resistant tuberculosis have shown a significant increase in the rate of sputum-culture conversion at 8 weeks of treatment (Table 2).^{64,65} Phase 3 trials of each drug are being initiated, and each manufacturer has applied for accelerated marketing approvals by regulatory agencies. Accelerated approval was recently granted by the Food and Drug Administration for the use of bedaquiline in multidrug-resistant tuberculosis.

Several studies of combination drugs are being conducted or are being planned, although these trials face barriers that include pharmacokinetic interactions, the reliance on clinical rather than surrogate end points, and the relatively low financial incentive for drug companies to perform such trials. The efficient evaluation of new drug combinations will require close cooperation among the drug companies and nonprofit sponsors of clinical trials. The three-drug combination of moxifloxacin, pyrazinamide, and PA-824 has 14-day bactericidal activity similar to that of standard four-drug therapy.⁶⁶ Linezolid has recently been shown to achieve sputum-culture conversion in patients with extensively drug-resistant tuberculosis, and further evaluations are under way.⁶⁷

BCG AND NEW VACCINES

M. bovis bacilli Calmette–Guérin (BCG) vaccine continues to be administered in infants at birth in most regions where tuberculosis is endemic. On the basis of a meta-analysis of controlled clinical trials, the vaccine has an estimated overall efficacy of approximately 50% for the prevention of tuberculosis.⁶⁸ Since the BCG vaccine can cause

fatal disseminated infection in immunosuppressed patients, it should not be administered in HIV-infected newborns. Although the BCG vaccine has never been routinely used in the United States, it is increasingly being considered for use in tuberculin-negative adults who are planning to travel to areas with a high prevalence of multidrug-resistant tuberculosis in order to provide medical care.

Through a major international effort, a range of vaccines, both as primary immunogens to replace BCG and as boosters for BCG, are being studied, with more than 30 vaccines in development. Twelve vaccines have entered clinical trials (Fig. S3 in the Supplementary Appendix).⁶⁹ A polyantigenic inactivated whole-cell vaccine showed 39% efficacy in a phase 3 trial for the prevention of tuberculosis among HIV-infected adults who had received previous BCG immunization.⁷⁰

CONCLUSIONS

Tuberculosis remains a major cause of death worldwide. The rise and spread of drug resistance and synergistic interaction with the HIV epidemic are posing difficult challenges and threatening global efforts at tuberculosis control. New molecular diagnostics have made earlier and improved diagnosis of active disease possible. Laboratory expertise and resources are required for these tests to become available throughout the developing world. Newer antituberculosis drugs offer the promise of shortened treatment regimens for drug-sensitive disease and more effective treatment for drug-resistant disease and latent infection. New vaccines against tuberculosis in advanced clinical trials offer hope for future tuberculosis control. Although these scientific developments are promising, the global economic crises continue to hinder tuberculosis-control programs. Strong political and financial commitments⁷¹ will be required to achieve global control of tuberculosis and avert millions of unnecessary deaths.

Dr. von Reyn reports receiving consulting fees from Oxford Immunotec. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank Sue Tvaroha for her assistance with Figure S1 in the Supplementary Appendix and Adam Zumla for administrative and technical support.

REFERENCES

1. Global tuberculosis report 2012. Geneva: World Health Organization (http://www.who.int/tb/publications/global_report/en/).
2. Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. *Bull World Health Organ* 2012;90:111D-119D.
3. Tuberculosis MDR-TB and XDR-TB: 2011 progress report. Geneva: World Health Organization, 2011 (http://www.who.int/tb/challenges/mdr/factsheet_mdr_progress_march2011.pdf).
4. Hill AN, Becerra J, Castro KG. Modeling tuberculosis trends in the USA. *Epidemiol Infect* 2012;140:1862-72.
5. Surveillance report: tuberculosis surveillance and monitoring in Europe 2012. Geneva: World Health Organization (<http://ecdc.europa.eu/en/publications/Publications/1203-Annual-TB-Report.pdf>).
6. Abubakar I, Lipman M, Anderson C, Davies P, Zumla A. Tuberculosis in the UK — time to regain control. *BMJ* 2011; 343:d4281.
7. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to *Mycobacterium tuberculosis*. *Am J Respir Crit Care Med* 2006;174:831-9.
8. Andrews JR, Noubary F, Walensky RP, et al. Risk of progression to active tuberculosis following reinfection with *Mycobacterium tuberculosis*. *Clin Infect Dis* 2012;54:784-91.
9. Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. *Am J Respir Crit Care Med* 2005;171:1430-5.
10. Lahey T, Mackenzie T, Arbeit RD, et al. Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. *Clin Infect Dis* 2013;56: 151-8.
11. Frieden TR, Munsiff SS, Ahuja SD. Outcomes of multidrug-resistant tuberculosis treatment in HIV-positive patients in New York City, 1990-1997. *Int J Tuberc Lung Dis* 2007;11:116.
12. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet* 2006;368:1575-80.
13. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. *Lancet* 2010;375: 1798-807.
14. Udawadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. *Clin Infect Dis* 2012;54: 579-81.
15. "Totally Drug-Resistant TB": a WHO consultation on the diagnostic definition and treatment options. Geneva: World Health Organization (http://www.who.int/tb/challenges/xdr/Report_Meeting_totallydrugresistantTB_032012.pdf).
16. Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis — critical steps for prevention and control. *N Engl J Med* 2010;363:1050-8.
17. Lawn SD, Zumla AL. Tuberculosis. *Lancet* 2011;378:57-72.
18. Caws M, Thwaites G, Dunstan S, et al. The influence of host and bacterial genotype on the development of disseminated disease with *Mycobacterium tuberculosis*. *PLoS Pathog* 2008;4(3):e1000034.
19. von Reyn CF. Optimal treatment of codisease due to HIV and tuberculosis. *J Infect Dis* 2011;204:817-9.
20. von Reyn CF, Kimambo S, Mtei L, et al. Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. *Int J Tuberc Lung Dis* 2011;15:1087-92.
21. Mudenda V, Lucas S, Shibemba A, et al. Tuberculosis and tuberculosis/HIV/AIDS-associated mortality in Africa: the urgent need to expand and invest in routine and research autopsies. *J Infect Dis* 2012;205:Suppl 2:S340-S346.
22. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. *Clin Infect Dis* 2005;40:1500-7.
23. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. *N Engl J Med* 2010;362:707-16.
24. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. *PLoS Med* 2011;8(1):e1000391.
25. Bates M, O'Grady J, Mwaba P, et al. Evaluation of the burden of unsuspected pulmonary tuberculosis and co-morbidity with non-communicable diseases in sputum producing adult inpatients. *PLoS One* 2012;7(7):e40774.
26. Horsburgh CR Jr, Rubin EJ. Latent tuberculosis infection in the United States. *N Engl J Med* 2011;364:1441-8.
27. Ferrara G, Murray M, Winthrop K, et al. Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNF α drugs. *Curr Opin Pulm Med* 2012;18:233-40.
28. Updated guidelines for using interferon gamma release assays to detect *Mycobacterium tuberculosis* infection — United States, 2010. *MMWR Morb Mortal Wkly Rep* 2010;59:1-25.
29. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: National Institute for Health and Clinical Excellence, 2011 (<http://www.nice.org.uk/nicemedia/live/13422/53642/53642.pdf>).
30. Use of interferon-gamma release assays in support of TB diagnosis. Stockholm: European Centre for Disease Prevention and Control, 2011 (http://ecdc.europa.eu/en/publications/Publications/1103_GUI_IGRA.pdf).
31. McNerney R, Maeurer M, Abubakar I, et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. *J Infect Dis* 2012;205:Suppl 2:S147-S58.
32. von Reyn CF, Horsburgh CR, Olivier KN, et al. Skin test reactions to *Mycobacterium tuberculosis* purified protein derivative and *Mycobacterium avium* sensiti among health care workers and medical students in the United States. *Int J Tuberc Lung Dis* 2001;5:1122-8.
33. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. *Lancet Infect Dis* 2006;6:710-25.
34. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. *N Engl J Med* 2010;363:1005-15.
35. Lawn SD, Kerkhoff AD, Vogt M, et al. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. *Clin Infect Dis* 2012;54:1071-9.
36. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva: World Health Organization, 2008 (http://www.who.int/tb/publications/2008/whohtmtb_2008_392/en/index.html).
37. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. *Eur Respir J* 2008;32:1165-74.
38. O'Grady J, Maeurer M, Mwaba P, et al. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. *Curr Opin Pulm Med* 2011;17: 134-41.
39. Performance of Xpert MTB/RIF version G4 assay. Geneva: Foundation for Innovative New Diagnostics, 2011 (<http://www.stop.tb.org/wg/gli/assets/documents/map/findg4cartridge.pdf>).
40. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational 'how-to': practical considerations. Geneva: World Health Organization.

- tion, 2011 (http://whqlibdoc.who.int/publications/2011/9789241501569_eng.pdf).
41. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. *N Engl J Med* 2006;355:1539-50.
 42. WHO policy on collaborative TB/HIV activities. Geneva: World Health Organization, 2012 (http://whqlibdoc.who.int/publications/2012/9789241503006_eng.pdf).
 43. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. *N Engl J Med* 2011;365:11-20.
 44. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization, 2011 (http://whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf).
 45. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. *N Engl J Med* 2011;365:2155-66.
 46. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. *Cochrane Database Syst Rev* 2010;1:CD000171.
 47. Samandari T, Agizew TB, Nyirenda S, et al. 6-Month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. *Lancet* 2011;377:1588-98.
 48. Lawn SD, Wood R. Antiretroviral therapy for control of the HIV-associated MDR and XDR tuberculosis epidemic in South Africa. *Am J Respir Crit Care Med* 2010;182:1567.
 49. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity and acceptability: the report of the final results. *Ann Intern Med* 1990;112:397-406.
 50. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. *N Engl J Med* 2011;365:1492-501.
 51. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. *N Engl J Med* 2011;365:1482-91.
 52. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. *N Engl J Med* 2011;365:1471-81.
 53. Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. *Ann Intern Med* 2012;157:313-24.
 54. Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. *Clin Infect Dis* 2011;53:716-24.
 55. ClinicalTrials.gov. Rifampin-based tuberculosis treatment versus rifabutin-based tuberculosis treatment in HIV (<http://clinicaltrials.gov/ct2/show/NCT01601626>).
 56. *Idem*. Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment (PrOMPT) (<http://clinicaltrials.gov/ct2/show/NCT01417988>).
 57. *Idem*. REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment (<http://clinicaltrials.gov/ct2/show/NCT01380080>).
 58. Guidelines for the programmatic management of drug resistant tuberculosis. Geneva: World Health Organization, 2011 (http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf).
 59. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. *Eur Respir J* 2011;38:516-28.
 60. Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. *Int J Tuberc Lung Dis* 2004;8:560-7.
 61. STREAM: the evaluation of a standardised treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (MDR-TB). 2011 (<http://www.controlled-trials.com/isrctn/pf/78372190>).
 62. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. *PLoS Med* 2012;9(8):e1001300.
 63. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. *Clin Infect Dis* 2010;51:6-14.
 64. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. *N Engl J Med* 2009;360:2397-405.
 65. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. *N Engl J Med* 2012;366:2151-60.
 66. Diacon AH, Dawson R, von Groote-Bidingmaier F, et al. 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. *Lancet* 2012;380:986-93.
 67. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. *N Engl J Med* 2012;367:1508-18.
 68. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. *JAMA* 1994;271:698-702.
 69. Stop TB Partnership. Tuberculosis vaccine candidates — 2011 (http://www.stoptb.org/wg/new_vaccines/assets/documents/TB%20Vaccine%20Pipeline_rAug%202012.pdf).
 70. von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. *AIDS* 2010;24:675-85.
 71. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. *Lancet* 2012;379:1902-13. [Erratum, *Lancet* 2012;379:2242.]

Copyright © 2013 Massachusetts Medical Society.

RECEIVE THE JOURNAL'S TABLE OF CONTENTS EACH WEEK BY E-MAIL

To receive the table of contents of the *Journal* by e-mail every Wednesday evening, sign up at NEJM.org.

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013;368:745-55.
DOI: 10.1056/NEJMra1200894

APPENDIX (WEB SUPPLEMENT)

<u>CONTENT</u>	<u>PAGE NO.</u>
AUTHOR NAMES AND INSTITUTIONAL DETAILS	Page 2
TABLE S1 GROUPS OF FIRST AND SECOND-LINE ANTI-TUBERCULOSIS DRUGS	Page 3
TABLE S2 MDR-TB TREATMENT DRUGS AND RELATED TOXICITIES	Page 4
TABLE S3 CANDIDATE TUBERCULOSIS DRUGS IN CLINICAL TRIALS	Page 6
FIGURE S1 RISKS OF <i>Mycobacterium tuberculosis</i> INFECTION AND DISEASE	Page 8
FIGURE S2 CLASSIFYING THE TUBERCULIN SKIN TEST REACTION	Page 9
FIGURE S3 GLOBAL TB VACCINE PIPELINE	Page 10
SUPPLEMENTARY REFERENCES TO TABLE 2	Page 11

Current Concepts

TUBERCULOSIS

ALIMUDDIN ZUMLA,M.D.,Ph.D., **MARIO RAVIGLIONE**,M.D., **RICHARD HAFNER**,M.D., AND **C. FORDHAM VON REYN**M.D.

From the Department of Infection, Center for Clinical Microbiology, Division of Infection and Immunity, University College London Medical School, University College London, U.K. (**A.Z**); STOP TB Department, World Health Organisation, Avenue Appia 20, 1211 Geneva 27, Switzerland (**M.R**); Tuberculosis Clinical Research Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892-7628, USA (**R.H**); Section of Infectious Disease and International Health, Geisel School of Medicine at Dartmouth, Hanover, NH 03756, USA (**C.FvR**).

TABLE S1**GROUPS OF FIRST AND SECOND-LINE ANTI-TUBERCULOSIS DRUGS**

GROUP NAME	ANTI-TUBERCULOSIS AGENT	ABBREVIATION
First- line oral agents	Isoniazid Rifampin/Rifampicin Ethambutol Pyrazinamide	H (Inh) R (Rif) E (Emb) Z (Pza)
Second-line parenteral agents (injectable anti-tuberculosis drugs)	Kanamycin Amikacin Capreomycin	Km Amk Cm
Fluoroquinolones	Levofloxacin Moxifloxacin Gatifloxacin Ofloxacin	Lfx Mfx Gfx Ofx
Oral bacteriostatic second-line anti- tuberculosis drugs	Ethionamide Prothionamide Cycloserine Terizidone Para-aminosalicylic acid	Eto Pto Cs Trd Pas
Group 5 anti-tuberculosis drugs	Clofazimine Linezolid Amoxicillin/Clavulanate Imipenem/Cilastin Clarithromycin	Cfz Lzd Amx/Clv Ipm/Cln Clr

TABLE S2

MDR-TB TREATMENT DRUGS AND RELATED TOXICITIES

GROUP	DRUG	SEVERE OR COMMON TOXICITIES	COMMENTS
Group 1 First-line Agents – Generally well tolerated	Pyrazinamide (Pza)*	- Hepatotoxicity (<1% with current dosing) - Hyperuricemia and gout - Anorexia, vomiting	- WHO guidelines recommend routine use despite 50% - 70% MDR resistance rates in some regions; reliable DST
	Ethambutol (Emb)*	- Central or peripheral retrobulbar neuritis in <1% cases	- No longer recommended for routine use in MDR-TB treatment because benefit not been shown
Group 2 Injectable Agents	Aminoglycosides: • Kanamycin (Km)* • Amikacin (Amk)	- Irreversible ototoxicity (6-18%) and in some cases may develop months after discontinuation	- Parenteral administration only - Km is preferred due to cost, but if resistance probable, Cm should be used
	Cyclic polypeptide: • Capreomycin (Cm)	- Nephrotoxicity - risk increased in elderly, renal impairment, and use with other nephrotoxic agents	- Cross-resistance patterns are variable and complex - local drug choice often made on basis of cost and availability
Group 3 Fluoroquinolones	Moxifloxacin (Mfx)*	- Generally well tolerated - GI disturbance - nausea, vomiting, diarrhea	- Optimal Mfx and Lfx doses not definitively established - Ofx substantially less potent - Use of ciprofloxacin is not recommended
	Levofloxacin (Lfx) Ofloxacin (Ofx)	- Neurologic disturbance – insomnia, restlessness; In less than 0.5%: agitation, confusion, depression - Dose-related QT prolongation common, so avoid use with long Q-T syndrome and caution with other drugs prolonging Q-T interval	
Group 4 Bacteriostatic Second-line Agents (in order of preference)	Ethionamide (Eto)	- Frequent GI intolerance – anorexia, nausea, vomiting, metallic taste	- Active against katG mutants, but not inhA and other relevant mutations
	Prothionamide (Pto)*	- Neurotoxicity: seizures, psychosis, depression - Peripheral and optic neuropathy - Hepatotoxicity (2%) - Hypothyroidism	- No substantial difference in toxicity between analogues - Divided doses (BID or TID) and/or initial dose ramping over 1-2 weeks may improve tolerance - Less effective with history of previous MDR- TB treatment - Pyridoxine should be added
	Cycloserine (Cs) Terizidone (Trd)	- Common CNS effects: mood changes, confusion, psychosis, paranoia, aggression, vertigo, tremor	- Terizidone may have less CNS toxicity, but not proven - Dose reduction common

GROUP	DRUG	SEVERE OR COMMON TOXICITIES	COMMENT
	Para-aminosalicylic acid (Pas)	- Frequent GI intolerance: anorexia, nausea, vomiting, diarrhea - Hepatotoxicity approx. 0.5% - Hypothyroidism	- High-dose pyridoxine (150-300 mg/day) should be added - Weak static activity only, but helps to prevent emergence of resistance - Granular form and divided dosing are usually better tolerated
Group 5 Agents with unclear role in MDR-TB Treatment (use only as needed for regimen to have at least 4 high-probability active second-line drugs)	High dose isoniazid (High-dose Inh)*	- Hepatotoxicity – Risk increases with age (2% with age > 50y), liver disease, other hepatotoxic drugs; - Rash (2%); - Neurotoxicity risk is increased with higher dose, CNS – seizure, hallucinations, mental changes, depression; - Peripheral neuropathy, rarely optic neuritis	- Unlikely to have activity against katG mutant strains, but may be active against most inhA mutant strains - Pyridoxine should be added
	Clofazimine (Cfz)*	- Red to brown skin discoloration with intensity related to dose and duration; - Dose-related GI disturbance: nausea, vomiting, And cramps - Q-T prolongation has been observed, but not carefully studied	- While role in treatment is not yet clear, has substantial activity in animal models - Optimal dosing not established - High barrier to resistance development - Extremely high/prolonged tissue and macrophage concentrations vs. serum
	Linezolid (Lzd)	- Nausea, diarrhea, and headache - With long-term use: Peripheral neuropathy, thrombocytopenia, infrequently optic neuropathy - Myelosuppression common; - Rarely, lactic acidosis, pancreatitis	- Has substantial sterilizing activity - High barrier to resistance - Relatively high cost - Dose reduction (600 daily to 300 mg daily) often required to allow continuation
	Amoxicillin/Clavulanate (Amx/Clv)	- Generally well tolerated - GI disturbance related to dose of Clv - Rarely, hypersensitivity/anaphylaxis	- Role in MDR-TB therapy not defined, but some case reports indicate possible benefit - Imp/Cln intravenous only - Emb may be synergistic and increases activity, even at sub-inhibitory concentrations
	Imipenam/Cilastatin (Imp/Cln)		
	Clarithromycin (Clr)	- Generally well tolerated; - GI disturbance common – nausea, cramping, diarrhea, abnormal taste - Q-T interval prolongation	- Potent inhibitor of CYP3A - Activity is low, but may synergize with Pza and activity may be significantly enhanced by Emb, if susceptible - High lung tissue levels

Abbreviations: DST = Drug susceptibility testing BID = twice daily dosing; TID = Thrice daily dosing

2011 WHO guidelines for choice of combination regimens for MDR treatment: Initiate treatment with Pza and four second-line drugs likely to be effective based on patient treatment history, local resistance and drug use patterns, and available DST of strains from patient or close contacts. Combination should include a fluoroquinolone (preferably Mfx or Lfx), an injectable drug, and eto (or pto) as first choices, if appropriate. Other drugs from Group 4 should be added in the order listed above to achieve combination goals. If other drugs are still needed, they are chosen from Group 5, and in that case, use of two Group 5 drugs may be considered. Addition of more drugs has not been demonstrated to add benefit in treatment of extensive disease. Intensive phase with at least five drugs (including an injectable and Pza) is continued for at least 8 months.

Maintenance therapy includes only the other drugs (typically a fluoroquinolone, Eto or Pto, and Cs or Trd). Total duration of therapy is at least 20 months in the absence of prior MDR treatment, but longer with previous MDR therapy (approximately 28-30 months). If available, DST should be obtained for fluoroquinolones and aminoglycosides. DST for other listed drugs is not reproducible or reliable (except for detection of inhA and KatG mutations). Regimen changes are made based on clinical and bacteriologic indicators of response and DST results.

HIV co-infection: All HIV co-infected patients treated for MDR-TB should begin antiretroviral therapy regardless of CD4+ cell count as soon as possible, but within 8 weeks of TB treatment initiation, and within 2 weeks for those with a CD4+ T cell count of less than 50 per cubic millimeter.

*** Drugs included in the (modified) Bangladesh Regimen:** *Intensive phase* consists of at least four months of Pza, Emb, Mfx, Clz, Km, high dose Inh, and Pto.

Maintenance phase includes Pza, Emb, Mfx, and Cfz to complete nine to twelve months total duration.

TABLE S3


CANDIDATE TUBERCULOSIS DRUGS IN CLINICAL TRIALS

CLASS	DRUG	TRIAL PHASE	DEVELOPER	MECHANISM OF ACTION	COMMENTS
Fluoroquinolone	Moxifloxacin	3	Bayer/GATB	-Inhibition of Topoisomerase IV and DNA gyrase	- Q-T interval prolongation: avoid use with long Q-T syndrome and caution when using with other drugs prolonging Q-T - Optimal doses not established - Gatifloxacin: More frequent dysglycemia; Not commercially available at present - Phase III trials to reduce treatment to 4 months: - Gatifloxacin (Oflo tub III trial)- results available mid-2013 - Moxifloxacin – REMox trial to be completed late 2014
	Gatifloxacin	3	WHO		
	Levofloxacin	2	Janssen; generics now available		
Nitroimidazole	Delamanid (OPC-67683)	3	Otsuka	-For replicating <i>M.tb</i> bacilli - inhibition of mycolic acid synthesis	- Q-T interval prolongation - Mild antagonism with bedaquiline, probably has no substantial effect on sterilizing activity of combination use - Delamanid - NDA for accelerated approval has been filed with EMA; Phase III trial initiated - Phase IIB trial of PA-824 in combination with Pza and Mfx initiated
	PA-824	2	GATB	-For non-replicating <i>M.tb</i> bacilli - generation of highly reactive nitrogen radicals	
Diarylquinoline	Bedaquiline (TMC-207)	2	Janssen	-Inhibition of ATP synthase	- Q-T interval prolongation - Metabolized by CYP3A4: with rifampin, AUC decreases by at least 50% - Excellent sterilizing activity and remarkable synergy with PZA - Prolonged tissue concentrations - Accelerated approval granted recently by the US Food and Drug Administration (FDA) for the treatment of multi-drug resistant tuberculosis. Phase III trial to begin mid-2013
Oxazolidinone*	Sutezolid (PNU 100480)	2	Pfizer	-Inhibition of translation by binding at the "A" site of peptidyl transferase center	- Whether hematologic and neurologic toxicity will be decreased vs. Linezolid is unknown - Appear to have good sterilizing activity - High barrier to development of resistance - Sutezolid Phase IIA (EBA) trial completed - AZD Phase IIA (EBA) trial now underway
	AZD 5847	2	Astra Zeneca		
Ethylenediamine	SQ109	2	Sequella	-Inhibition of MmpL3 transporter of trehalose mycolate across cell membrane for incorporation into cell wall	- Phase 2b MAMS trial will evaluate four new treatment regimens including SQ109, an increased dose of Rif, and Mfx, in early 2013 - Appears to have high barrier to development of resistance

* Two other oxazolidinones now in late clinical trials for other indications have substantial activity against *Mycobacterium tuberculosis*: Tedazolid (Trius) and Radezolid (Rib-X)

EBA = Early bactericidal activity. GATB = The Global Alliance for Tuberculosis Drug Development

FIGURE S1
RISKS OF *Mycobacterium tuberculosis* INFECTION AND DISEASE



Percentages represent the estimated risk of progression from latent infection to active disease in a general population. The right side of the Figure depicts the relative risk of developing active tuberculosis after new exposure for subjects with and without prior mycobacterial experience including BCG, LTBI, or active tuberculosis. The risk of disease after new exposure is shown as 1X for naïve subjects and is higher or lower depending on prior mycobacterial experience.

FIGURE S2


CLASSIFYING THE TUBERCULIN SKIN TEST (TST) REACTION

TST INDURATION	INTERPRETATION
5mm induration	Considered positive in: HIV-infected individuals Recent contacts of active TB case Old healed TB Transplant patients Chronic liver or renal failure patients Immunosuppressed patients
10mm induration	Considered positive in: Foreign born from high TB endemic regions IV drug abusers Laboratory or health personnel Staff and residents of high congregate settings Children less than 5 years or active TB case in the family
15mm induration	Considered positive in: All cases

Note:

- Targeted TST programs should be conducted amongst high risk groups
- TST reaction may be negative in patients with LTBI
- Rule out active TB disease before treating LTBI

FIGURE S3
GLOBAL TB VACCINE PIPELINE



SUPPLEMENTARY REFERENCES TO TABLE 2

REMox -- Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis (REMoxTB). ClinicalTrials.gov Identifier: NCT00864383.

OFLOTUB III -- A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis ClinicalTrials.gov Identifier: NCT00216385.

RIFAQUIN -- An international multicentre controlled clinical trial to evaluate high dose RIFapentine and a QUINolone in the treatment of pulmonary tuberculosis RIFAQUIN. International Standard Randomised Controlled Trial Number Register Identifier: ISRCTN44153044.

INCREASED DOSE RIFAMYCINS (Multiple trials)

-RIFAPENTINE studies

-- **Study of Daily Rifapentine for Pulmonary Tuberculosis.** ClinicalTrials.gov Identifier: NCT00814671.

-- **TBTC Study 29** -Rifapentine During Intensive Phase Tuberculosis (TB) Treatment. ClinicalTrials.gov Identifier: NCT00694629.

-RIFAMPIN studies

-- **High RIF** -Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With PulmonaryTuberculosis (High RIF). ClinicalTrials.gov Identifier:NCT00760149.

-- **HR-1** -Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB (HR1). ClinicalTrials.gov Identifier: NCT01392911.

BEDAQUILINE -- (Ref 64) -- Diacon AH, Donald PR, Pym A, *et al.* The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009 Jun 4;360(23):2397-405.

BEDAQUILINE -- (Ref 66) -- Diacon AH, Dawson R, von Groote-Bidlingmaier *et al.* 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial Lancet. 2012 Sep 15;380(9846):986-93.

-- Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis. ClinicalTrials.gov Identifier: NCT01215851

DELAMANID -- (Ref 65) -- Gler MT, Skripconoka V, Sanchez-Garavito E, *et al.* Delamanid for multidrug-resistant pulmonary tuberculosis. *N Engl J Med.* 2012 Jun 7;366(23):2151-60.

DELAMANID -- Safety and Efficacy Trial of Delamanid for 6 Months in Patients With Multidrug Resistant Tuberculosis. ClinicalTrials.gov Identifier: NCT01424670 (Phase 3 trial by Otsuka).

PA-824 -- Diacon AH, Dawson R, du Bois J, *et al.* Phase II dose-ranging trial of the early bactericidal activity of PA-824. *Antimicrob Agents Chemother.* 2012 Jun;56(6):3027-31.

PA-824 -- Singh R, Manjunatha U, Boshoff HI, *et al.* PA-824 kills nonreplicating *Mycobacterium tuberculosis* by intracellular NO release. *Science.* 2008 Nov 28;322(5906):1392-5.

PA-824 -- (Ref 66) -- Diacon AH, Dawson R, von Groote-Bidlingmaier *et al.* 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial *Lancet.* 2012 Sep 15;380(9846):986-93.

PA-824 -- Evaluation of 8 weeks treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB). ClinicalTrials.gov Identifier: NCT01498419 (ongoing Phase IIB trial for the Global Alliance's PA-824+PZA+moxifloxacin combination).

PA-824 -- Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824(Pa)-Pyrazinamide(Z). ClinicalTrials.gov Identifier: NCT01691534. (Not yet initiated).

LINEZOLID -- (Ref 67) -- Lee M, Lee J, Carroll MW, *et al.* Linezolid for treatment of chronic extensively drug-resistant tuberculosis. *N Engl J Med.* 2012;367(16):1508-18.

SUTEZOLID -- A Study Of PNU-100480 In Newly Diagnosed, Treatment Sensitive Patients With Pulmonary Tuberculosis To Assess Early Bactericidal Activity (EBA) And Whole Blood Activity (WBA). ClinicalTrials.gov Identifier: NCT01225640

-- Wallis RS, Friedrich SO, Diacon AH, *et al.* Bactericidal Activity in Sputum and Blood of PNU-100480(Sutezolid,U-480) and its Major Metabolite (PNU101603,U-603) in Patients with Pulmonary TB. ICAAC 201 abs A-1264.

AZD5847 -- Phase 2a EBA Trial of AZD5847. ClinicalTrials.gov Identifier: NCT01516203.

SQ-109 -- Dose Escalation Study of SQ109 in Healthy Adult Volunteers. ClinicalTrials.gov Identifier: NCT00866190
-- Dose Escalation Study of SQ109 in Healthy Adult Volunteers, International Consortium for Trials of Chemotherapeutic Agents in Tuberculosis, 2012 Meeting: <http://www.intertb.sgul.ac.uk/2012-meeting>.

SQ-109 -- A multiple arm, multiple stage (MAMS), phase 2, open label, randomized, controlled clinical trial to evaluate four treatment regimens including two doses of SQ109, an increased dose of rifampicin, and moxifloxacin in adult subjects with newly diagnosed, smear-positive pulmonary tuberculosis - PanACEA-MAMS-TB-01. Pan-African Clinical Trials Registry Identifier: PACTR201205000383208.

ACTG 5290 -- (Ref 55) -- Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV. <http://clinicaltrials.gov/ct2/show/NCT01601626>.

PROMPT -- (Ref 56) -- Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment (PrOMPT). ClinicalTrials.gov Identifier: NCT01417988.

REMEMBER (ACTG 5274) -- (Ref 57) -- Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment. AC ClinicalTrials.gov Identifier: NCT01380080.

ACTG 5279 -- Evaluating the Safety and Effectiveness of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection. ClinicalTrials.gov Identifier: NCT01404312.